Open AccessP061: Safety and Dose‐Expansion Study of Combination Favezelimab (anti–LAG‐3) Plus Pembrolizumab in Anti–PD‐1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Author(s) -
Borchmann Peter,
Johnson Nathalie A.,
Lavie David,
Gregory Gareth,
Herrera Alex F.,
Minuk Leonard,
Vucinic Vladan,
Armand Philippe,
Avigdor Abraham,
Gasiorowski Robin,
Herishanu Yair,
Keane Colm,
Kuruvilla John,
Palcza John,
Pillai Pallavi,
Nahar Akash,
Timmerman John
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000890812.66186.e8
Subject(s) - medicine , pembrolizumab , cohort , refractory (planetary science) , lymphoma , oncology , cancer , immunotherapy , physics , astrobiology